Immunovant, Inc. is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in Durham, NC. Its latest filed balance sheet (2026-03-31) shows total assets of $957 million (its filed statements).
Pre-revenue companyBiological Products, (No Diagnostic Substances)Durham, NCfilings since 20193 of 9 filed, 6 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a pre-revenue company: no meaningful revenue on file yet (industry code 2836), so it is read as a pre-revenue company; the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 5.7 out of ten, 3 of 9 metrics filed and 6 estimated: past 5.2 out of ten, present 5.0 out of ten, future 6.5 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 5.8 out of ten. 1 warning event since 2019; the latest 2019-12-20. 58th percentile among 159 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 4.9 out of ten. CrossAssetData estimate 4.9/10, confidence 20 of 100 (family median). 50th percentile among 103 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Shareholder treatment (past): 5.2 out of ten. CrossAssetData estimate 5.2/10, confidence 35 of 100 (one part). 52nd percentile among 146 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 5.9 out of ten. ROE -59%: lost 59¢ per shareholder dollar. Leverage 11%: owes 11¢ per asset dollar. 59th percentile among 147 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 4.9 out of ten. CrossAssetData estimate 4.9/10, confidence 20 of 100 (family median). 50th percentile among 102 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Leadership (present): 3.8 out of ten. bottom 38% of 108 in its family for leadership; chief executive since 2025. 38th percentile among 108 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 9.6 out of ten. CrossAssetData estimate 9.6/10, confidence 35 of 100 (one part). 96th percentile among 152 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Growth drivers (future): 4.9 out of ten. CrossAssetData estimate 4.9/10, confidence 20 of 100 (family median). 50th percentile among 101 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Expectations vs reality (future): 5.1 out of ten. CrossAssetData estimate 5.1/10, confidence 20 of 100 (family median). 50th percentile among 73 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
The filing record
Newest annual report: Form 10-K filed 2026-05-20 for the period ended 2026-03-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-06 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-06 (on EDGAR). Newest filing: Form 4, 2026-10-09. Filings on record since 2019. Read from EDGAR 2026-10-12.
Who runs it
Venker, Eric (Chief Executive Officer); Girao, Tiago (Chief Financial Officer); Gloria, Melanie (Chief Operating Officer); Stout, Jay S (Chief Technology Officer); Van, Tuyl Christopher (Chief Legal Officer); Geffner, Michael (Chief Medical Officer); Pande, Atul (director); Fromkin, Andrew J. (director); Susman, Robert Graham (director); Bauer, Jake (director); and 3 more. 13 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-09.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.